Ophthalmic Business News

Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.

On this episode, Laura Enyedi, MD, is live from the Women in Ophthalmology meeting with Pratap Challa, MD, Fasika Woreta, MD, Jennifer Lindsey, MD, and Annie Wishna, MD, discussing residency programs.

ATSN-201 received orphan drug designation from the FDA for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release.

Saving money at an early age is perhaps the simplest and one of the most effective methods to accumulate wealth.

Sonoma Pharmaceuticals and EMC Pharma have entered into a co-marketing agreement to expand their eye care product lines, according to a press release.

The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

One important investment vehicle to understand when working toward slow and steady growth is the index fund.

Ocuphire Pharma has dosed the first participants in the VEGA-3 phase 3 clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, according to a press release.